Physician profile
Iouri Sobol
NPI 1134124464
$2,412.88
in general payments reported to CMS, 2019-2025
19 companies · $168 in 2025
The $168 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $286 · 2021: $456 · 2022: $441 · 2023: $367 · 2024: $288 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $823.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $681.04 | 2019-2025 | Verquvo, Lagevrio, Capvaxive |
| Amarin Pharma, INC. | $273.56 | 2019-2022 | |
| Lilly USA, LLC | $265.90 | 2019-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $180.19 | 2022-2025 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $172.09 | 2021-2023 | |
| Pfizer INC. | $133.03 | 2021-2024 | |
| Amgen INC. | $121.38 | 2020-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $90.07 | 2019-2024 | Breztri |
| Abbvie INC. | $83.39 | 2020-2025 | |
| Gilead Sciences, INC. | $70.46 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.60 | 2019-2024 | Jardiance |
| Phathom Pharmaceuticals, INC. | $63.57 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $56.20 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $41.89 | 2022 | |
| Janssen Pharmaceuticals, INC | $32.70 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $25.00 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $20.00 | 2021 | |
| Allergan, INC. | $17.14 | 2019 | |
| Circassia INC. | $16.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iouri Sobol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.